Trial intelligence / Profile preview

Dexmedetomidine during IRE for solid tumours

NCT02044224Phase 4

Key facts

Status: Completed
Start: Jan 2014
Primary completion: Sep 2015
Countries: 1
Sponsor: Akademiska sjukhuset
Modality: Small Molecules

Drugs: dexmedetomidine
Conditions: liver cancerpancreatic cancer (PC)

Overview

Phase 4, open-label, single-arm trial of dexmedetomidine in liver cancer and pancreatic cancer (PC), sponsored by Akademiska sjukhuset. Primary endpoint: Patient Satisfaction With Anaesthesia Technique at 4 hours. Started Jan 2014; status: completed.

Design

1 arm

Study design: Non-randomizedOpen-label

Dexmedetomidine
Dexmedetomidine infusion during anaesthesia for IRE procedure

Who it enrols

Adult patients with liver or pancreas cancer scheduled for IRE procedure, excluding those with pregnancy, allergy to anesthesia, severe heart block, stroke, or refractory hypotension.

Endpoints

Primary

Patient Satisfaction With Anaesthesia Technique4 hours

Secondary

Evaluation of anaesthetic consumptionDuring anaesthesia
Vital signs: blood pressure, oxygen saturation, heart rate, breathing rate4 hours
Postoperative analgesic requirements24 hours
Maximal pain intensity24 hours
Description of patient characteristics1 week before

Beyond the preview

Go deeper on NCT02044224.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02044224.